Redhill Biopharma - ADR

NASDAQ:RDHL   3:59:54 PM EDT
5.12
+0.13 (+2.60%)
Products

Redhill Says Opaganib Phase 2/3 COVID-19 Study Endpoints Did Not Achieve Statistical Significance

Published: 09/14/2021 12:42 GMT
Redhill Biopharma - ADR (RDHL) - Redhill Biopharma Reports Top-line Data From Opaganib Phase 2/3 Study in Severe Covid-19 Patients.
Redhill Biopharma Ltd - Study Endpoints Did Not Achieve Statistical Significance.
Redhill Biopharma Ltd - Top-line Safety Data Showed Good Tolerability of Opaganib, With Balanced Adverse Events Between Study Arms.